Landos Biopharma, Inc.
Lanthionine synthetase C-like 2-based therapeutics

Last updated:

Abstract:

Provided are compounds that target the lanthionine synthetase C-like protein 2 pathway. The compounds can be used to treat a number of conditions, including infectious disease, autoimmune disease, diabetes, and a chronic inflammatory disease.

Status:
Grant
Type:

Utility

Filling date:

15 Oct 2019

Issue date:

16 Jun 2020